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Abstract
Background: [−2]proPSA and its derivatives have an higher diagnostic accuracy than PSA in predicting prostate
cancer (PCa). In alternative to PSA, ultrasensitive PSA (uPSA) and [−2]proPSA could be potentially useful in recurrent
disease detection. This research focused on [−2]proPSA and uPSA fluctuations over time and their possible clinical
and pathological determinants, in the first year after RP.
Methods: A cohort of 106 consecutive patients, undergoing RP for high-risk prostate cancer (pT3/pT4 and/or positive
margins), was enrolled. No patient received either preoperative/postoperative androgen deprivation therapy or
immediate adjuvant RT, this latter for patient choice. [−2]proPSA and uPSA were measured at 1, 3, 6, 9, 12 months after
RP; their trends over time were estimated by the mixed-effects linear model. The uPSA relapse was defined either as 3
rising uPSA values after nadir or 2 consecutive uPSA >0.2 ng/ml after RP.
Results: The biochemical recurrence (BCR) rate at 1 year after RP was either 38.6 % (in case of 3 rising uPSA values) or
34.9 % (in case of PSA >0.2 ng/ml after nadir), respectively. The main risk factors for uPSA fluctuations over time were
PSA at diagnosis >8 ng/ml (p = 0.014), pT (p = 0.038) and pN staging (p = 0.001). In turn, PSA at diagnosis >8 ng/ml
(p = 0.012) and pN (p < 0.001) were the main determinants for [−2]proPSA trend over time. In a 39 patients subgroup,
uPSA decreased from month 1 to 3, while [−2]proPSA increased in 90 % of them; subsequently, both uPSA and
[−2]proPSA increased in almost all cases. The [−2]proPSA trend over time was independent from BCR status
either in the whole cohort as well in the 39 men subgroup.
Conclusions: Both uPSA and [−2]proPSA had independent significant fluctuations over time. PSA at diagnosis
>8 ng/ml and pathological staging significantly modified both these trends over time. Since BCR was not
confirmed as determinant of [−2]proPSA fluctuations, its use as marker of early biochemical relapse may not be
actually recommended, in an high-risk prostate cancer patients population.
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Background
After a successful radical prostatectomy (RP), a serum
detectable Prostate Specific Antigen (PSA) may be
considered a marker of residual prostate tissue, pre-
sumably anticipating either locoregional or systemic
disease [1].
However, approximately 20 % of patients experience
biochemical recurrence (BCR) after RP [2–4]; around
30 % of them will ultimately develop a clinical progres-
sion [5, 6].
Several trials proved that adjuvant radiation therapy
(RT) after RP decreases BCR risk and provides survival
benefit, in high-risk disease patients. An early and reli-
able BCR detection is therefore crucial, since postopera-
tive RT is more effective when given to subjects having
low PSA levels [7].
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New PSA ultrasensitive methods detect levels <0.1 ng/
ml, and some assays even minimal ones (1 pg/ml) [8, 9].
A classical definition for ultrasensitive PSA (uPSA) re-
lapse is 3 rising uPSA values after nadir [10]; recurrence
seldom occurs in patients with uPSA <0.04 ng/ml,
3 years after RP [11].
In recent years, many efforts were made to improve
the biomarkers diagnostic accuracy for prostate cancer
(PCa); at the same time, an alternative to PSA as BCR
marker is still unavailable. Some studies showed that
[−2]proPSA and its derivatives improve PSA accuracy in
predicting PCa at prostate biopsy (Bx), being associated
to PCa aggressiveness either at Bx or at final pathology
after RP [12, 13]. Moreover, [−2]proPSA could be poten-
tially useful in recurrent disease detection, a virtually un-
explored field.
To our knowledge, no study investigated the
[−2]proPSA trend over time post-RP. We enrolled at
RP a sequential cohort of high-risk PCa patients (extra
prostate disease and/or positive margins), eligible for
adjuvant RT but not being given for patient choice.
The primary endpoint of this research was to longitu-
dinally investigate either [−2]proPSA and uPSA time
trends as well their clinical and pathological determi-
nants, in the first year after RP, at a single high-volume
institution. The secondary endpoint was to elucidate a
[−2]proPSA possible role in early BCR detection.
Methods
A cohort of 106 consecutive patients, undergoing robot
assisted radical prostatectomy (RARP) for a pathological
high-risk PCa (pT3/pT4 and/or positive margins), was en-
rolled at San Luigi Gonzaga Hospital - Orbassano (Italy)
from September 2013 to October 2014. Among them, 83
patients (81.3 %) underwent robot-assisted extended pel-
vic lymph nodes dissection prior to RARP (external iliac
artery/vein, obturator fossa, obturator nerve, internal iliac
artery/presacral lymph nodes) [14]. Lymphadenectomy
was planned according to Briganti nomogram [15]. Patho-
logical staging was performed according to the TNM Clas-
sification of Malignant Tumors seventh edition [16];
histological grading was assessed according to the Gleason
grading system [17]. No patient received either preopera-
tive/postoperative androgen deprivation therapy or imme-
diate adjuvant RT, this latter for patient choice.
The follow-up was scheduled at 1/3/6/9/12 months
after RARP; it included a complete physical and digital
rectal examination (DRE), as like [−2]proPSA and uPSA
measurements. The uPSA relapse was defined either as
3 rising uPSA values after nadir [10] or two consecutive
uPSA >0.2 ng/ml rising after RP [18].
Due to the observational nature of this research and
according to Italian regulation, no formal IRB/IEC ap-
proval was needed [19].
uPSA and [−2]proPSA serum concentrations measurement
Serum samples were analysed by the Access 2 Immuno-
assay System on a UniCell DxI800 instrument (Beckman
Coulter, USA). The calibration procedure was performed
by a 7-point recombinant [−2]proPSA curve (0–5000 pg/
ml). The blank and quantitation limits (according to the
Clinical Laboratory Standards Institute document EP17-
A) were 0.5 and 3.23 pg/ml, respectively. uPSA results
were obtained by a single determination, while that
from [−2]proPSA by a duplicate one; the analyses were
repeated in case of coefficient of variation >20 %. All
analyses were performed in the same laboratory (Can-
diolo Cancer Institute).
Statistical methods
The primary outcomes were the uPSA and [−2]proPSA
trends over time after RARP and their potential modifica-
tions by independent covariates. uPSA and [−2]proPSA
were longitudinally measured at five time-points (1/3/6/9/
12 months after RP), and these repeated measures were
used as dependent variables in univariate and multivariate
mixed-effects linear models [20]. Due to the not-Gaussian
distribution of uPSA and [−2]proPSA, all models were es-
timated using their log-transformed values [ln(uPSA) and
ln [−2]proPSA]. At first, the univariate analyses were per-
formed for the following covariates: age (>65 vs. ≤65 years),
Body Mass Index [BMI, (>26 vs. ≤26)], DRE (positive vs.
negative), PSA at diagnosis (>8 vs. ≤8 ng/ml), number of
positive Bx samples (>5 vs. ≤5), GS at Bx (8–9 vs. ≤7),
number of lesions at Magnetic Resonance Imaging [MRI
(≥2 vs. 1)], prostate volume (>40 vs. ≤40 ml), tumor per-
centage (>10 % vs. ≤10 %), GS at surgery (8–9 vs. ≤7), cap-
sule/vesicles/neural/vascular/marginal involvement (any
vs. none), pT (pT3b vs. pT3a vs. pT2), pN (pN+ vs. pN0)
and BCR (any vs. none). Two different definitions of BCR
were used: either uPSA value >0.2 ng/ml or 3 rising uPSA
values after nadir. The multivariate mixed-effects linear
models for uPSA and [−2]proPSA trends over time were
estimated by the restricted maximum likelihood method,
using a first-order autoregressive covariance matrix: both
ln(uPSA) and ln([−2]proPSA) variances at each time-point
were considered comparable and constant, while the cor-
relations between subsequent measures similar. Patient
characteristics were analyzed by the Fisher’s exact test for
categorical variables, while for continuous ones by the
Mann–Whitney and Kruskal-Wallis tests (for independent
measures) or by the Wilcoxon and Friedman ones (for
repeated measures). All results for continuous variables
were expressed as the median (range). All reported p-
values were obtained by the two-sided exact method, at
the conventional 5 % significance level. Data were ana-
lysed as of September 2015 by R 3.2.1 (R Foundation
for Statistical Computing, Vienna-A, http://www.R-
project.org).
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Results
The main patient characteristics (106 patients) are re-
ported in Table 1. The 1-year after surgery BCR rate
was 34.9 % using uPSA value > 0.2 ng/ml, while 38.6 %
using 3 rising uPSA values after nadir; at the same
time, no subject had an imaging-confirmed metastatic
disease.
The uPSA values sequentially increased in 43.4/69.8/
83.1/89.0 % patients, at 3/6/9/12 months after RARP, re-
spectively. The uPSA trend over time was confirmed by
the Friedman test (p < 0.001); using the Wilcoxon one,
all the differences between two adjacent time-points
were extremely significant (p < 0.001), except that be-
tween 1 vs. 3 months (p = 0.833).
The mixed-effects linear model was used to confirm
the uPSA time trend (within-subject factor) and to esti-
mate its potential risk factors (between-subject factors)
(Table 2, Fig. 1a). This approach confirmed that uPSA
fluctuations over time were statistically significant (p <
0.001). In the multivariate mixed-effects linear model,
the main determinants for uPSA fluctuations were PSA
at diagnosis >8 ng/ml (p = 0.014), pT (p = 0.038) and pN
(p = 0.001).
The [−2]proPSA values sequentially increased in 86.8/
93.4/90.4/91.5 % patients, at 3/6/9/12 months after sur-
gery, respectively. The difference among the median
[−2]proPSA repeated measures was highly significant at
the Friedman test (p < 0.001); all the differences between
adjacent time-points were extremely significant (p <
0.001), when investigated by the Wilcoxon test.
Using the mixed-effects linear model as for uPSA,
[−2]proPSA fluctuations over time were statistically sig-
nificant (p < 0.001) (Table 2, Fig. 1b). Their main predic-
tors were PSA at diagnosis >8 ng/ml (p = 0.012) and pN
(p < 0.001); the interaction between them was marginal
(p = 0.099).
In 39 patients, uPSA decreased from month 1 to 3,
conversely [−2]proPSA increased in 90 % of them; in the
further follow-up, both uPSA and [−2]proPSA increased
in almost all cases.
Of note, [−2]proPSA trend over time was independent
from BCR status (p = 0.096 and 0.194 according to BCR
definitions, respectively; Fig. 2a, b) in the whole cohort as
well in the 39 men subgroup (its BCR rate was 33.3 %).
When BCR was calculated as uPSA >0.2 ng/ml, the 1-year
[−2]proPSA was around double for BCR patients
Table 1 Main patient characteristics
Age at diagnosis, years 65 (48–77)
PSA at diagnosis, ng/ml 7.8 (4.0–81.0)
BMI at diagnosis, kg/m2 26.3 (17.4–34.6)
Prostate volume, ml 41.2 (22.4–103.9)
Tumor percentage, % 10.2(2.3–52.9)
Cancer familiarity,
neg 6 (5.7 %)
pos 100 (94.3 %)
DRE,
neg 71 (67.6 %)
pos 34 (32.4 %)
GS at biopsy,
6 31(29.5 %)
7(3 + 4) 29(27.6 %)
7(4 + 3) 21(20.0 %)
8 16(15.2 %)
9 8(7.6 %)
Lesions at MRI,
1 31 (53.4 %)
2+ 27 (46.6 %)
GS at surgery,
6 4(3.8 %)
7(3 + 4) 37(37.4 %)
7(4 + 3) 37(37.4 %)
8 15(15.2 %)
9 6(6.1 %)
Margins,
neg 53 (50.0 %)
pos 53 (50.0 %)
Capsule involvement,
neg 25 (23.6 %)
pos 81 (76.4 %)
Neural involvement,
neg 8 (7.5 %)
pos 98 (92.5 %)
Vascular involvement,
neg 65 (68.4 %)
pos 30 (31.6 %)
pT2 9 (8.5 %)
pT3a 83 (78.3 %)
pT3b 14 (13.2 %)
pN0 69 (79.3 %)
pN+ 18 (20.7 %)
Table 1 Main patient characteristics (Continued)
uPSA, ng/ml
1/3/6/9/12 months
0.010 (0–1.15)/0.018 (0–0.67)/
0.051 (0.01–0.52)/0.100 (0.01–0.56)/
0.154 (0–0.89)
[−2]proPSA, pg/ml
1/3/6/9/12 months
0.22 (0–2.14)/0.57 (0–2.84)/0.89 (0–3.97)/
1.25 (0.03–3.72)/1.38 (0–4.86)
For continuous variables, all the results are expressed as median (range)
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compared to no-BCR ones (its observed marginal means
were 0.31–0.54–0.87–1.17–1.33 pg/ml for BCR subjects
and 0.41–0.77–1.31–1.64–2.17 pg/ml for no-BCR ones).
When BCR was calculated as 3 rising uPSA values after
nadir, [−2]proPSA increased over time with a superim-
posable pattern (0.31–0.60–0.93–1.35–1.50 pg/ml for
BCR subjects and 0.37–0.61–1.09–1.32–1.65 pg/ml for
no-BCR ones).
Discussion
Recently, while many efforts have been made to improve
the biomarkers diagnostic accuracy for PCa, an alterna-
tive to PSA as BCR marker is still lacking.
A persistently elevated or rising PSA after RP identifies
an heterogeneous patient population, having highly vari-
able prognosis and controversial management. Several
trials showed that adjuvant RT after RP decreases BCR
risk and provides survival benefit for high-risk patients
[21–23]. Conversely, surgical treatment would not have
failed in up to 50 % of patients receiving adjuvant RT:
thus, they would have been unnecessarily exposed to ra-
diations. To minimize overtreatment, RT should be re-
served only for confirmed recurrences; however, an early
salvage RT has not been proven to be equivalent to adju-
vant RT yet.
uPSA is an interesting tool, whose variations could
foresee a BCR [11]; this finding rarely occurs in patients
with very low uPSA nadir after RP [24]. However, the
uPSA role after RP is not fully defined yet. Recently,
Seikkula investigated uPSA after RP and the possible
correlation of uPSA doubling time (uPSA-DT) with trad-
itional PSA doubling time (PSA-DT); uPSA >0.03 ng/ml
emerged as good relapse predictor, while the above correl-
ation between was marginal [25].
Therefore, new biomarkers for risk stratification after
RP are required. Several studies demonstrated that the
[−2]proPSA truncated form is detectable in tumor extracts
and its serum values are markedly associated with PCa
[26–30]. Sokoll demonstrated that [−2]proPSA may im-
prove PCa detection: its raising is associated with an ag-
gressive disease [31]. Le showed that this biomarker was
able to discriminate PCa from benign disease, in males
with PSA 2.5–10 ng/ml and negative DRE [27]. Recently,
Guazzoni confirmed that [−2]proPSA and its derivatives
are associated with PCa volume and aggressiveness [13].
Nevertheless, well considering that [−2]proPSA and its
derivatives have an higher diagnostic performance than
PSA, the potential usefulness of this PSA isoform in the
detection of recurrent disease post radical treatment is
still quite unexplored.
Table 2 Mixed linear models for uPSA and [−2]proPSA repeated measures
uPSA Univariate model Multivariate model [−2]proPSA Univariate model Multivariate model
Covariate p p Covariate p p
Time trend <0.001 <0.001 Time trend <0.001 <0.001
Age >65 years 0.095 0.455 Age >65 years 0.472
BMI >26 0.059 0.507 BMI >26 0.315
PSA at diagnosis >8 ng/ml 0.015 0.014 PSA at diagnosis >8 ng/ml 0.032 0.012
Positive DRE 0.168 Positive DRE 0.241
Biopsy samples >5 0.365 Biopsy samples >5 0.483
GS at biopsy >7 0.419 GS at biopsy >7 0.349
MRI lesions >1 0.178 MRI lesions >1 0.607
Prostate volume >40 ml 0.214 Prostate volume >40 ml 0.472
Tumor percentage >10 % 0.522 Tumor percentage >10 % 0.658
Positive margins 0.018 0.214 Positive margins 0.822
GS at surgery >7 0.209 GS at surgery >7 0.102
Capsule involvement 0.039 Capsule involvement 0.077
Neural involvement 0.216 Neural involvement 0.603
Vascular involvement 0.110 Vascular involvement 0.083 0.952
pT <0.001 0.038 pT 0.008 0.879
pN <0.001 0.001 pN 0.008 <0.001
BCR (uPSA +0,2 ng/ml) 0.096
BCR (3 rising uPSA values) 0.194
pT*pN (interaction) - 0.639 PSA at diagnosis*pN (interaction) - 0.099
p-values
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Fig. 1 a, b uPSA and [−2]proPSA mean observed values at 1–3–6–9–12 months after radical prostatectomy
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Fig. 2 a, b [−2]proPSA mean observed values at 1–3–6–9–12 months after radical prostatectomy by both BCR definitions (bcr = uPSA value increasing
0.2 ng/ml; bcr3 = 3 rising uPSA values after nadir)
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Sottile investigated the role of [−2]proPSA in the iden-
tification of patients with metastatic progression after
RP [32]. In this study, 76 patients with BCR were retro-
spectively studied; the imaging performed at BCR time
confirmed metastatic disease in 31 out of them. Serum
samples were collected at the time of imaging-confirmed
metastatic progression. Median PSA, free PSA (fPSA),
%fPSA, [−2]proPSA and PHI were compared between
metastatic and non-metastatic patients; [−2]proPSA was
a statistically significant predictor of imaging-proven
metastatic PCa. However, [−2]proPSA was assessed only
at BCR time, so no information may be derived on its
potential role, in predicting subsequent clinical progres-
sion, when measured at BCR time [32].
The current trial is the first investigating [−2]proPSA
fluctuations over time post-RP, and their possible deter-
minants in an high-risk PCa patients cohort.
The [−2]proPSA time trend in the first 3 months
showed a different pattern, compared to uPSA one.
While uPSA had quite stable levels in two thirds of cases
(slowly increasing only in the next period), [−2]proPSA
showed a constant linear increase.
The main risk factors for uPSA fluctuations were PSA
at diagnosis, pT and pN staging, being PSA at diagnosis
and pN the only ones for [−2]proPSA variations.
A secondary endpoint was to investigate [−2]proPSA
potential role as BCR early biomarker, in comparison to
uPSA: in our series, the [−2]proPSA trend over time was
independent from BCR status.
Our study has some points of strengths. The main one
is that our results may suggest a stop in further re-
searches for [−2]proPSA in the post RP arena. Second, it
was designed as observational study in a homogeneous
cohort of men with high-risk PCa, candidates for RP. Fi-
nally, we adopted a standardized centralised pathological
evaluation; all blood samples were managed in the same
laboratory according to Semjonow guidelines: no ar-
chived serum were used [33].
Conclusions
[−2]proPSA and uPSA showed significant fluctuations
over time after RP, with an independent pattern. PSA at
diagnosis and pathological staging significantly modified
both these trends. Since BCR was not confirmed as a
modifier of [−2]proPSA time trend, its use as marker of
an early biochemical relapse may not be actually recom-
mended, among high-risk prostate cancer patients.
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